智飞生物(300122) - 2018 Q1 - 季度业绩预告

Financial Performance - The company expects net profit for Q1 2018 to be between 230 million and 270 million CNY, representing an increase of 281.32% to 347.63% compared to the same period last year[2] - The net profit for the same period last year was 60.31 million CNY[2] - Non-recurring gains are expected to impact net profit by approximately 3.6 million CNY, with a net profit increase of 275.35% to 341.66% after excluding these gains[6] - The performance forecast is based on preliminary estimates from the company's finance department, with detailed financial data to be disclosed in the Q1 report[6] - The performance forecast has not been audited by registered accountants[3] Sales and Product Development - The significant increase in profit is attributed to strong sales of self-developed products and the introduction of the four-valent HPV vaccine, which began sales in November 2017[4] - The four-valent HPV vaccine has been successfully bid in 26 provinces and municipalities in mainland China, leading to steady sales growth[4] - The company is focused on vaccine production, sales, and promotion, with all operations progressing as planned[4] Investment Advisory - Investors are advised to make cautious decisions and be aware of investment risks[7] - The company emphasizes that non-recurring gains will not have a significant impact on overall performance[6]